Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

10.6K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
10.6K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

716
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
716
Types of RNA01:23

Types of RNA

63.6K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
63.6K
RNA Interference01:23

RNA Interference

26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computational selection of allosteric RNAs: A review.

International journal of biological macromolecules·2026
Same author

Rational Design of Chimeric Antisense Oligonucleotides that Target FMN Riboswitch mRNAs and Inhibit the Growth of Methicillin-Resistant <i>Staphylococcus aureus</i>.

ACS infectious diseases·2025
Same author

Targeting Bacterial Adenylate Kinase mRNA with a Chimeric Antisense Oligonucleotide for Rational Antibacterial Drug Development.

Molecules (Basel, Switzerland)·2025
Same author

Computational Design of Allosteric Ribozymes via Genetic Algorithms.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

General and Specific Cytotoxicity of Chimeric Antisense Oligonucleotides in Bacterial Cells and Human Cell Lines.

Antibiotics (Basel, Switzerland)·2024
Same author

Targeting FMN, TPP, SAM-I, and glmS Riboswitches with Chimeric Antisense Oligonucleotides for Completely Rational Antibacterial Drug Development.

Antibiotics (Basel, Switzerland)·2023
Same journal

Correction: Coulter et al. OrgTRx: A Platform Developed in Queensland for the Extraction and Visualisation of Antimicrobial Susceptibility Data for the Surveillance of Resistance in Microorganisms. <i>Antibiotics</i> 2026, <i>15</i>, 63.

Antibiotics (Basel, Switzerland)·2026
Same journal

Clinical Outcomes and Safety Profile of Vancomycin in Outpatient Parenteral Antimicrobial Therapy Services: A Systematic Review.

Antibiotics (Basel, Switzerland)·2026
Same journal

Ciprofloxacin-Based Ionic Liquids Increase Mutation Frequency in <i>Escherichia coli</i>.

Antibiotics (Basel, Switzerland)·2026
Same journal

Bacteriophages as Potential Sustainable Alternatives to Antibiotics for Controlling <i>Salmonella</i> in the Poultry Value Chain.

Antibiotics (Basel, Switzerland)·2026
Same journal

Inhibition of Quorum Sensing-Controlled Virulence Factors and Biofilm in <i>Pseudomonas aeruginosa</i> by <i>Piper</i> Species.

Antibiotics (Basel, Switzerland)·2026
Same journal

Antibiotic Use in the Community: Behavioural, Contextual, and System-Level Determinants.

Antibiotics (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.5K

Antisense and Functional Nucleic Acids in Rational Drug Development.

Robert Penchovsky1, Antoniya V Georgieva1, Vanya Dyakova1

  • 1Laboratory of Synthetic Biology and Bioinformatics, Faculty of Biology, Sofia University, "St. Kliment Ohridski", 8 Dragan Tzankov Blvd., 1164 Sofia, Bulgaria.

Antibiotics (Basel, Switzerland)
|March 27, 2024
PubMed
Summary
This summary is machine-generated.

Antisense and functional nucleic acids offer rational drug design, reducing costs and improving success rates. These RNA-based tools serve as both drug targets and therapeutics for efficient drug development.

Keywords:
antisense oligonucleotidesantisense therapiesdrug deliverydrug discoverynucleic acid engineeringriboswitchesribozymes

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1000
An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA
07:55

An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA

Published on: February 17, 2023

3.6K

Related Experiment Videos

Last Updated: Jun 29, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1000
An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA
07:55

An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA

Published on: February 17, 2023

3.6K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Discovery

Background:

  • Nucleic acids play dual roles in drug development as targets and therapeutics.
  • RNA targets include messenger RNA, non-coding RNAs, and ribozymes.
  • Antisense and functional nucleic acids are valuable tools in drug discovery.

Purpose of the Study:

  • To review the design principles, applications, and prospects of antisense and functional nucleic acids in drug development.
  • To highlight the potential of RNA-based approaches for rational drug design and target assessment.
  • To promote novel RNA-based strategies for the pharmaceutical industry and patient benefit.

Main Methods:

  • Review of existing literature on antisense and functional nucleic acids.
  • Discussion of RNA-based control of gene expression mechanisms.
  • Exploration of engineering approaches for novel drug discovery.

Main Results:

  • Antisense oligonucleotides, synthetic ribozymes, and siRNAs are key examples of functional nucleic acids.
  • These molecules enable rational drug design, enhancing efficiency and success rates.
  • RNA-based drug development offers new avenues for antibacterial therapies.

Conclusions:

  • Antisense and functional nucleic acids represent a powerful platform for rational drug design.
  • These approaches can significantly reduce drug development time and cost.
  • RNA-based therapeutics hold great promise for future medicine.